Also known as Recombinant human insulin · rhInsulin · regular insulin · Humulin · Novolin
The archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.
Insulin is the hormone that defined the biologic era. It is a small but genuinely complex protein: two peptide chains — an A chain of 21 residues and a B chain of 30 — held together by two interchain disulfide bonds, with a third disulfide looping within the A chain. At ~5.8 kDa it is the smallest hormone in this catalog’s biologic tier, yet it is assembled, folded, and processed exactly like the larger proteins, and it was the molecule that proved recombinant human therapeutics were possible.
Insulin is synthesized in the body as a single chain — preproinsulin → proinsulin — that folds and forms its disulfide bonds before a connecting C-peptide is excised, leaving the mature two-chain hormone. That biosynthetic detail is why early recombinant manufacturing expressed the A and B chains (or proinsulin) in bacteria and then handled folding and disulfide pairing as a controlled step: the chemistry that the body does enzymatically has to be reproduced and verified in a reactor. Get the disulfides wrong and you get a misfolded, inactive — or immunogenic — product.
Its history is foundational twice over. Insulin was discovered in 1921 in Toronto by Banting, Best, Macleod, and Collip, and the patent was famously sold to the university for one dollar on the principle that "insulin belongs to the world." Six decades later, in 1982, recombinant human insulin (Humulin) became the first recombinant-DNA drug ever approved — the proof of concept for the entire modern biologic industry, including most of the engineered peptides elsewhere in this catalog.
And then the American drama. Despite the dollar patent and a century of manufacturing experience, US insulin list prices roughly tripled between 2002 and 2013, pushing some patients to ration a drug they cannot live without — a recurring, deadly access failure that sits uncomfortably against the molecule’s origin story. For a reference that takes provenance and honest pricing seriously, insulin is the clearest case study in the gap between what a medicine costs to make and what it is sold for.
Insulin is also widely misunderstood at the edges: it is occasionally misused in bodybuilding for its anabolic effects, where dosing errors cause life-threatening hypoglycemia, and the modern GLP-1 era has shifted public perception of what "diabetes medicine" even means. It remains, first and foremost, essential replacement therapy for type 1 diabetes and an important tool in advanced type 2.
Binds the insulin receptor, a tyrosine kinase, triggering autophosphorylation and the PI3K/AKT cascade that drives GLUT4 translocation and glucose uptake into muscle and fat, suppresses hepatic glucose output, and promotes glycogen, lipid, and protein synthesis.
Behind every vial of Insulin (human) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Insulin (human), specifically, is brought into being.
On paper, Insulin (human) is C257H383N65O77S6 — about 5,808 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Insulin (human)'s chain is short but unusual — it carries non-natural residues that help it resist enzymatic breakdown, but demand specialized, costlier building blocks and careful coupling on the synthesizer. It also carries a disulfide bridge, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Insulin (human) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Insulin (human) proves itself: identity confirmed by mass spectrometry against its ~5,808 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Insulin (human) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Recombinant human insulin is expressed in E. coli or yeast — historically as separate A and B chains or as proinsulin — then folded, disulfide-paired, and (for the proinsulin route) enzymatically processed to remove C-peptide. Release testing is protein-specific: identity by peptide mapping and mass spectrometry, correct disulfide connectivity, potency by bioassay, plus host-cell-protein and endotoxin limits. This is biologic manufacturing, not peptide synthesis.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Insulin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A 51-amino-acid protein hormone made of two disulfide-linked chains that lowers blood glucose by driving its uptake into cells. Recombinant human insulin is produced in engineered bacteria or yeast and was the first recombinant-DNA drug approved (1982).
It is a folded, multi-chain protein whose activity depends on correct disulfide pairing, and it is produced in living cells. Its manufacturing and quality control are protein-grade, not the solid-phase synthesis used for short research peptides.
The original patent was sold for $1, but modern insulin products, manufacturing, and the US pricing system are separate from that history. List prices rose sharply in the 2000s–2010s, a widely documented access problem.
No. This is a research and educational reference. Insulin has a narrow safety margin and is a prescription medicine; nothing here is dosing guidance.